Coronavirus Disease 2019 Clinical Trial
Official title:
The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With Coronavirus Disease 2019
Verified date | February 2020 |
Source | Second Affiliated Hospital of Xi'an Jiaotong University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
As of February 17th, 2020, China has 76396 confirmed cases of coronavirus disease 2019 (COVID-19), including 2348 deaths. Although the impact factors of clinical outcomes among hospitalized patients still need to be clarified, some of the therapeutic regimens have shown the potency in the treatment of severe cases. Investigators aim to evaluate the efficacy of psychological and physical rehabilitation based humanistic care in the treatment of COVID-2019.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 15, 2020 |
Est. primary completion date | April 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Inpatients with 2019 Novel Coronavirus infection Exclusion Criteria: - Patients can not follow-up; - Investigator considering inappropriate. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital of Xi'an Jiaotong University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recovery Time | Time for recovery from admission to discharged | 1 month | |
Secondary | Self-rating depression scale | Self-rating depression scale will be finished from patients by a scale table designed by investigator | 1 month | |
Secondary | Survival rate | Survival rate of the patient after treatment | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05091411 -
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
|
Phase 3 | |
Completed |
NCT05107375 -
Clinical Study of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Combined With Influenza Vaccine
|
Phase 3 | |
Active, not recruiting |
NCT05128643 -
Clinical Study on the Immune Program of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell)
|
Phase 3 | |
Completed |
NCT04988217 -
Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
|
Phase 1/Phase 2 | |
Completed |
NCT04579393 -
Fostamatinib for Hospitalized Adults With COVID-19
|
Phase 2 | |
Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
Completed |
NCT04646044 -
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
|
Phase 1 | |
Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
Recruiting |
NCT05092568 -
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
|
||
Completed |
NCT05364268 -
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
|
||
Completed |
NCT06189040 -
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
|
Phase 4 | |
Recruiting |
NCT04401436 -
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
|
||
Not yet recruiting |
NCT04395742 -
1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
|
||
Recruiting |
NCT04388631 -
Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
|
||
Completed |
NCT05501288 -
Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019
|
N/A | |
Active, not recruiting |
NCT05216471 -
Identify Coronavirus Disease by Chest X-ray
|
||
Terminated |
NCT04672564 -
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
|
Phase 3 | |
Completed |
NCT04967781 -
Autoimmunity Contributes to the Severe Progression of COVID-19
|
||
Completed |
NCT04678830 -
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
|
Phase 2 |